invIOs Successfully Raises €8.2 Million for Immuno-Oncology Pipeline
invIOs GmbH, a pioneering biotechnology firm focused on developing advanced cancer therapies, has recently announced a significant funding achievement. The company successfully raised €8.2 million in a Series A fundraising round with substantial involvement from current investors, including Ligand Pharmaceuticals. This influx of capital will support the progress of its therapeutic pipeline and aid in reaching crucial preclinical and clinical milestones.
Continuing Pipeline Progress with New Funding
The new funding solidifies invIOs' strategy to progress its pipeline, particularly two primary programs aimed at addressing cancer challenges. The company is actively moving forward with INV501 and INV441, both of which are underpinned by vital collaborations with the prestigious Dana-Farber Cancer Institute (DFCI).
Key Developments in Cancer Therapies
INV501, an oral small molecule, is making headway with its development. The team at DFCI expects to provide details regarding its mechanism of action and validation by early 2025, presenting an exciting outlook for this promising cancer treatment.
Advancements in Cell Therapy
INV441, a cell therapy option, has also shown substantial progress. A successful pre-IND meeting has positioned it for a first-in-humans study targeting glioblastoma, anticipated to kick off mid-2025. These initiatives have garnered praise from invIOs management, reflecting their deep commitment to transforming cancer treatment.
Statements from invIOs Leadership
Peter Llewellyn-Davies, the CEO & CFO of invIOs, expressed gratitude for the strong backing from existing and new shareholders. He emphasized that this financial support empowers invIOs to push forward with its crucial programs without delay. Romana Gugenberger, Chief Medical and Scientific Officer at invIOs, shared enthusiasm for the collaborations with DFCI, highlighting the potential impact of their novel therapies on treating aggressive tumors.
Investing in the Future of Cancer Treatments
invIOs is dedicated to the ongoing development of its innovative therapies through rigorous preclinical testing. INV501 has demonstrated promising preclinical efficacy against multiple solid tumors, and its ability to cross the blood-brain barrier presents a compelling advantage. The company is also advancing INV441, which utilizes modified tumor-infiltrating lymphocytes (TILs) directed at combatting glioblastoma through personalized immunotherapy.
Upcoming Events and Investor Engagement
Investors and interested parties will have the opportunity to engage directly with invIOs management during the LSX Inv€$tival Showcase™. The event is aimed at creating avenues for discussion about the company's innovative cancer therapies and future directions. Meetings can be arranged with Peter Llewellyn-Davies and Romana Gugenberger, who are both looking forward to sharing insights and milestones.
About invIOs
invIOs GmbH is a forward-thinking biotechnology company headquartered in Vienna. The firm is committed to unlocking the potential of the immune system in the fight against cancer. With expert-driven approaches focusing on personalized treatments, invIOs aims to make significant strides in improving patient outcomes.
Frequently Asked Questions
What recent funding has invIOs secured?
invIOs has raised €8.2 million in Series A funding to bolster its cancer therapy pipeline.
What are the key products in invIOs' pipeline?
The primary products include INV501, an oral small molecule, and INV441, a cell therapy for glioblastoma.
How does INV501 improve cancer treatment?
INV501 enhances T cell-mediated immune responses, showing promise against breast cancer and melanoma.
When is invIOs planning to initiate human trials for its therapies?
INV441's first-in-humans study is expected to start in mid-2025.
How can interested investors meet with invIOs management?
Investors can arrange meetings during the LSX Inv€$tival Showcase™, where company executives will present their plans.
